comparemela.com

Latest Breaking News On - Phillip zamore - Page 1 : comparemela.com

From Novel Science to Impactful Treatments: RNAi Journey

From Novel Science to Impactful Treatments: RNAi Journey
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United-states
Ruth-lehmann
Thomas-tuschl
Dave-bartel
Kevin-fitzgerald
Phil-sharp
David-bartel
Paul-schimmel
Phillip-zamore
Drug-administration
Novartis
Alnylam-pharmaceuticals

Taking RNAi from interesting science to impactful new treatments

Taking RNAi from interesting science to impactful new treatments
mit.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mit.edu Daily Mail and Mail on Sunday newspapers.

United-states
Dave-bartel
Ruth-lehmann
Phil-sharp
Paul-schimmel
Thomas-tuschl
David-bartel
Phillip-zamore
Kevin-fitzgerald
Novartis
Alnylam-pharmaceuticals
Drug-administration

Two UMass Chan professors elected to National Academy of Medicine

Two UMass Chan professors elected to National Academy of Medicine
wbjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wbjournal.com Daily Mail and Mail on Sunday newspapers.

Katherine-fitzgerald
Umass-chan
Roger-davis
Phillip-zamore
Robert-brown
Umass-chan-medical-school-in-worcester
National-academy-of-medicine
Chan-medical-school
National-academy
Job-dekker

Alnylam Pharmaceuticals, Inc. Forecasted to Earn Q1 2024 Earnings of ($1.58) Per Share (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) – Analysts at Zacks Research reduced their Q1 2024 EPS estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Thursday, June 1st. Zacks Research analyst A. Chakroborty now anticipates that the biopharmaceutical company will earn ($1.58) per share for the quarter, down from […]

Thomas-tuschl
Jeffreyv-poulton
Phillip-zamore
David-bartel
International-biotechnology-trust
Nasdaq
Alnylam-pharmaceutical
Sumitomo-mitsui-financial-group
Hedge-funds-weigh-in-on-alnylam-pharmaceuticals
Alnylam-pharmaceuticals
Prelude-capital-management
News-ratings-for-alnylam-pharmaceuticals-daily

The Manufacturers Life Insurance Company Sells 495,795 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

The Manufacturers Life Insurance Company decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 59.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 343,220 shares of the biopharmaceutical company’s stock after selling 495,795 shares during the quarter. […]

United-kingdom
Thomas-tuschl
Jeffreyv-poulton
Phillip-zamore
David-bartel
Exchange-commission
Sumitomo-mitsui-financial-group
Quarter-for-alnylam-pharmaceuticals
Nasdaq
Manufacturers-life-insurance-company
Gulf-international-bank-united-kingdom-ltd
Alnylam-pharmaceuticals-stock

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.